rs121434569
|
|
Secondary malignant neoplasm of liver
|
|
0.020 |
GeneticVariation
|
BEFREE |
First-line gefitinib, longer EGFR TKI treatment duration, male, initial liver metastasis and uncommon EGFR mutations may be independent factors for secondary EGFR T790M mutation.
|
30485437 |
2019 |
rs121434569
|
|
Secondary malignant neoplasm of liver
|
|
0.020 |
GeneticVariation
|
BEFREE |
After her death, an autopsy revealed SCLC transformation and EGFR T790M secondary mutation (T790M) as mutually exclusive resistance mechanisms occurring differently in different metastases; two liver metastases (SCLC versus AC with T790M) and two lymph node metastases (SCLC versus AC with T790M) were analyzed to compare the expression status of immune markers by immunohistochemistry and by an immune oncology gene expression panel.
|
28193529 |
2017 |
rs1042522
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
The p53 R72P genotype was identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 78 consecutive colorectal cancer patients with liver metastases and 214 age- and sex-matched cases with nonmetastatic colorectal cancer.
|
18988302 |
2008 |
rs104886003
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
As a proof of the concept, we present the case of a metastatic patient with a PIK3CA wild-type primary tumor in which the PIK3CA E545K mutation was identified in both the circulating-free DNA obtained from a peripheral blood sample and in the formalin-fixed, paraffin-embedded liver metastasis.
|
26001593 |
2015 |
rs1052133
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
Increased frequency of Ser/Ser genotype of hOGG1 Ser326Cys was found to be associated both with higher grade (p = 0.001, OR: 6.4; 95% CI: 2.69-62.69) and liver metastasis (p = 0.005, OR: 7.5; 95% CI: 0.7-68.36).
|
21561390 |
2011 |
rs1057519698
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
Sequencing analyses of DNA from a liver metastasis biopsy sample and circulating tumor DNA both found the same I1171N ALK kinase domain mutation, known to confer resistance to certain ALK inhibitors.
|
27565911 |
2016 |
rs1057519742
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
We report a case of a 46-year-old female with recurrent blue nevus-like melanoma of the scalp with liver metastases; mutational analysis showed GNA11 Q209L and BAP1 Q393 mutations.
|
27152652 |
2016 |
rs1057519803
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
Whole-exome sequencing of the primary HER2-negative breast cancer and its HER2-negative synchronous liver metastasis from a 46-year-old female revealed the presence of an activating and clonal HER3 G284R mutation.
|
25953157 |
2015 |
rs1057519847
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
However, patients with EGFR 19del and LM showed marginally significantly shorter OS (P = .0531) and patients with EGFR L858R and LM had OS similar to that of patients without LM (P = .1883).
|
28549835 |
2017 |
rs1057519848
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
However, patients with EGFR 19del and LM showed marginally significantly shorter OS (P = .0531) and patients with EGFR L858R and LM had OS similar to that of patients without LM (P = .1883).
|
28549835 |
2017 |
rs1057519909
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
Biopsy of a patient's progressing liver metastasis following prolonged response to cetuximab revealed a MEK1(K57T) mutation as a novel mechanism of acquired resistance.
|
26644315 |
2016 |
rs1131691014
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
The p53 R72P genotype was identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 78 consecutive colorectal cancer patients with liver metastases and 214 age- and sex-matched cases with nonmetastatic colorectal cancer.
|
18988302 |
2008 |
rs113488022
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
BRAF V600E and SRC mutations were mutually exclusive, and SRC mutation was significantly associated with left-sided tumor and liver metastasis compared to BRAF V600E mutation (P = 0.016 and P = 0.025, respectively).
|
30792536 |
2019 |
rs121434568
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
However, patients with EGFR 19del and LM showed marginally significantly shorter OS (P = .0531) and patients with EGFR L858R and LM had OS similar to that of patients without LM (P = .1883).
|
28549835 |
2017 |
rs1217691063
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
677C>T and 1298A>C genotypes were determined simultaneously by melting curve analyses on liver metastases.
|
15608557 |
2004 |
rs121913247
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
Finally, a <i>MET</i>ex14 del mutation-positive NSCLC patient who responded to crizotinib but later relapsed, demonstrated a mixed response to glesatinib including reduction in size of a <i>MET</i> Y1230H mutation-positive liver metastasis and concurrent loss of detection of this mutation in plasma DNA.<b>Conclusions:</b> Together, these data demonstrate that glesatinib exhibits a distinct mechanism of target inhibition and can overcome resistance to type I MET inhibitors.<i></i>.
|
28765324 |
2017 |
rs121913250
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
KRAS c.34G>A mutation was detected in primary tumor and liver metastasis, which additionally revealed 2 rare PI3KCA mutations (c.1633G>C and c.1645G>C).
|
29409955 |
2018 |
rs121913377
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
BRAF V600E and SRC mutations were mutually exclusive, and SRC mutation was significantly associated with left-sided tumor and liver metastasis compared to BRAF V600E mutation (P = 0.016 and P = 0.025, respectively).
|
30792536 |
2019 |
rs121913530
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
KRAS c.34G>A mutation was detected in primary tumor and liver metastasis, which additionally revealed 2 rare PI3KCA mutations (c.1633G>C and c.1645G>C).
|
29409955 |
2018 |
rs1345316856
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
Cell lines stably expressing mutant PRPK (S250A), knockdown TOPK, knockdown PRPK or knockdown of both TOPK and PRPK significantly inhibited liver metastasis of human HCT116 colon cancer cells in a xenograft mouse model.
|
28412249 |
2017 |
rs1452020002
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
The SMAD4 (N129K and G508D) mutations observed in P2-1, however, were nor detected in H2.
|
25623536 |
2015 |
rs2910164
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
miR-146a Polymorphism (rs2910164) Predicts Colorectal Cancer Patients' Susceptibility to Liver Metastasis.
|
27824903 |
2016 |
rs397507444
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
677C>T and 1298A>C genotypes were determined simultaneously by melting curve analyses on liver metastases.
|
15608557 |
2004 |
rs397517096
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
L747P (2239-2240 TT>CC) in exon 19 is a rare EGFR mutation that appears to lead to gefitinib resistance and might accelerate liver metastases.
|
26339441 |
2015 |
rs4872077
|
|
Secondary malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
A novel germline truncating mutation of DR5/TNFRSF10B was identified, and DR4/TNFRSF10A SNP rs4872077 was associated with the development of liver metastases (p = 0.02).
|
18590575 |
2008 |